Group 1 - The core viewpoint of the articles highlights that the company, Jinxin Reproductive Medicine (01951), has shown resilience in its IVF cycle numbers, with a projected improvement in Q4 2025 compared to Q3 2025, despite an 8.0% decline in H1 2025 compared to H1 2024 [1] - The overall decline in IVF cycles has narrowed from -5.2% in the first three quarters of 2024 to -1.4% for the entire year of 2025, indicating a recovery trend [1] - The flagship hospital in Chengdu has seen a turnaround, with IVF cycles growing by 1.3% in 2025 compared to a decline of -1.9% in the first three quarters of 2025 [1] Group 2 - Looking ahead to 2026 and beyond, the company plans to enhance clinical treatment outcomes, patient care quality, and service supply levels, while accelerating the upgrade of core reproductive medical technologies [2] - The company aims to strengthen its market position in Chengdu and expand its capacity in the Greater Bay Area following the relocation of new facilities, while also addressing overseas policy changes to tap into international market growth potential [2] - The company intends to leverage national fertility support policies and industry development opportunities to solidify its competitiveness and provide high-quality medical services, ultimately creating long-term stable value for shareholders [2]

下表載列本集團自有醫院和投資－營運－移交（「IOT」）協議或管理服務協議（「MSA」）1 管 理的醫院及診所於截至2025年12月31日止年度及截至2025年9月30日止九個月的IVF取卵 周期數，連同2024年同期的比較數據： Jinxin Fertility Group Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 1951 * 自願公告 2025年第四季度的主要營運數據 本公告乃由錦欣生殖醫療集團有限公司*（「本公司」）自願刊發，旨在使本公司股東及潛在 投資者了解本公司及其附屬公司（「本集團」）的最新業務進展。 本公司董事會（「董事會」）欣然宣佈，通過持續不斷的優化運營措施，於2025年第四季 度，本集團的體外受精（「IVF」）取卵周期數較2025年第三季度有了進一步提升。儘管2025 年上半年業績較2024年同期下滑8.0%，但本集團2025年大中華區業務仍展現出強勁韌 性，全年業績相較2024年僅微降0.4%，已基本回升至 ...

致：香港交易及結算所有限公司 公司名稱: 錦欣生殖醫療集團有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025 ...

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Jinxin Fertility (01951.HK) by 513,500 shares on December 30, with a total net reduction of 5.981 million shares over the last five trading days and 15.8205 million shares over the last 20 trading days [1] - As of now, southbound funds hold 1.462 billion shares of Jinxin Fertility, accounting for 53.0% of the company's total issued ordinary shares [1] - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services, along with various medical services and sales of medical consumables and equipment, mainly in China and the United States [1]

Group 1 - The seminar on building a fertility-friendly society gathered public hospital managers and reproductive industry experts to discuss China's current fertility situation and the implementation of fertility support policies [1] - The Director of the National Health Commission's Maternal and Child Health Center emphasized the importance of establishing a fertility support service system to improve population health and sustain economic development [2][3] - The need for a reproductive medicine system that addresses current challenges, such as long treatment cycles and uneven distribution of medical resources, was highlighted by experts [4][5] Group 2 - A report on improving the assisted reproductive process was presented, suggesting measures like enhancing health insurance policies and patient experience [6] - Experts shared experiences on enhancing clinical diagnosis and treatment levels in assisted reproduction, with a focus on innovative diagnostic solutions and collaboration with local healthcare facilities [10] - The integration of AI and information technology in hospitals was discussed as a means to improve patient experience and streamline processes in assisted reproduction [11][12]

Group 1 - Southbound funds increased their holdings in Jinxin Fertility (01951.HK) by 3.07 million shares on December 22 [1] - Over the past 5 trading days, there were 2 days of net reductions totaling 147,500 shares [1] - In the last 20 trading days, there were 11 days of net increases totaling 8.775 million shares [1] Group 2 - As of now, southbound funds hold 1.466 billion shares of Jinxin Fertility, accounting for 53.16% of the company's issued ordinary shares [1] - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers assisted reproductive services, management services, ambulatory surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as sales of medical consumables and equipment, mainly in China and the United States [1]

Core Viewpoint - The "Annual Excellence IR Team (Small and Medium Market Capitalization)" award recognizes outstanding investor relations (IR) teams of listed companies for their significant contributions to industry transformation and development [4]. Group 1: Award Announcement - The "Annual Excellence IR Team (Small and Medium Market Capitalization)" award was presented during the "Technology Empowerment · Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1]. - Ten companies were awarded the "Annual Excellence IR Team (Small and Medium Market Capitalization)" award, including Beikang Medical-B (02170.HK), Gushengtang (02273.HK), Huitongda Network (09878.HK), Jinxin Fertility (01951.HK), Kunbo Medical-B (02216.HK), Lianlian Digital (02598.HK), Qingsi Games (06633.HK), TCL Electronics (01070.HK), Yaxin Technology (01675.HK), and Zhaoke Ophthalmology-B (06622.HK) [1]. Group 2: Evaluation Criteria - The award evaluation focused on the construction of communication channels between IR teams and investors, emphasizing the importance of long-term perspectives on companies' overall performance [4]. - The selection process involved quantitative data analysis and expert review to determine the final results [4]. Group 3: Broader Context - Gelonghui aims to create a reference value ranking of listed companies and unicorns in the investment community, covering all listed companies on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4].

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights a concentrated trend of domestic innovative drug collaborations and transactions as the year ends, with expectations for value recovery in 2026 [1][4] - The overall market performance shows a decline, with the Hang Seng Index down 0.8% and the Hang Seng Healthcare Index down 4.3% during the week [4][7] - The report emphasizes the importance of stock selection logic returning to fundamentals and valuations, focusing on stocks that are currently undervalued with expected fundamental improvements [4] Valuation Summary - The report provides a detailed valuation overview of various companies, indicating target prices and earnings per share estimates for FY25E and FY26E, along with their respective price-to-earnings ratios [3] - Notable companies with "Buy" ratings include AstraZeneca, BeiGene, and Hansoh Pharmaceutical, with target prices significantly above current trading prices [3] Market Trends - The report notes a slight decrease in domestic institutional holdings through the Hong Kong Stock Connect, while foreign holdings remain stable [33] - The report identifies a trend of increasing positions in leading innovative pharmaceutical companies by domestic investors, particularly in companies like Heng Rui Medicine and Rongchang Bio [36] Investment Insights - The report mentions several significant business development (BD) transactions exceeding $1 billion, indicating a robust pipeline for innovative drugs [4][5] - It recommends focusing on specific segments such as innovative drugs and CXO companies that are expected to benefit from downstream recovery and high market demand [4]

Group 1 - The company, Jinxin Reproductive Medicine (01951.HK), announced a share buyback on December 17, 2023, spending HKD 12.121 million to repurchase 4.825 million shares [1]

Group 1 - The company, Jinxin Reproductive Medicine (01951), announced a share buyback plan on December 17, 2025, involving an expenditure of HKD 12.121 million to repurchase 4.825 million shares [1]